BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Genetown

  AVEO Oncology Announces Phase 1 Results from TiNivo Study to be Presented at the 16th International Kidney Cancer Symposium

  AVEO Oncology today announced that results from the Phase 1 portion of the Phase 1/2 TiNivo study will be presented in an oral presentation at the 16th International Kidney Cancer Symposium, to be held November 3-4, 2017 in Miami.

  October 16, 2017

   · 

  6 min read
• Policy

  Aries Pharma Release: FDA accepts New Drug Application for Methylene Blue MMX and sets PDUFA Date for May 21, 2018

  Aries Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA date of May 21st, 2018, for its decision on the New Drug Application (NDA) for Methylene Blue MMX (MB MMX).

  October 16, 2017

   · 

  5 min read
• HyperMed Imaging Announces Sales Availability for Its New HyperView Product

  HyperMed Imaging, Inc. announced today that the company is now offering for sale its new HyperView Imaging System to customers in the United States.

  October 16, 2017

   · 

  3 min read
• Drug Development

  Omeros Announces Upcoming Presentation of Clinical OMS721 Data at European Society for Blood and Marrow Transplantation

  Omeros today announced that data will be presented from the company’s Phase II clinical trial of OMS721,

  October 16, 2017

   · 

  6 min read
• Trillium Therapeutics’ TTI-621 Program Featured at the EORTC CLTF Cutaneous Lymphoma Conference

  Trillium Therapeutics announced today that new preclinical data and a patient case study for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the EORTC CLTF meeting “Cutaneous Lymphomas - Insights and Therapeutic Progress”, October 13-15, in London, England.

  October 16, 2017

   · 

  6 min read
• Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer

  Novocure announced today five data presentations at the International Associations for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer, October 15 to October 18 in Yokohama, Japan.

  October 16, 2017

   · 

  4 min read
• Drug Development

  Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients

  Halozyme today announced initiation of a clinical trial evaluating its investigational new drug PEGPH20 with atezolizumab (TECENTRIQ).

  October 16, 2017

   · 

  5 min read
• Biotech Beach

  Thermo Fisher Scientific’s Oncomine Dx Target Test for Non-Small Cell Lung Cancer Receives Coverage from First Regional Health Plan

  Thermo Fisher Scientific today announced its Oncomine Dx Target Test has received a positive coverage decision by Regence BlueCross/BlueShield.

  October 16, 2017

   · 

  2 min read
• Business

  Hoth Therapeutics Announces The Addition Of Dr. Richard D Granstein, M.D. To The Company’s Technology Advisory Board

  Hoth Therapeutics announced today the addition of Dr. Richard D. Granstein, M.D., to the Company’s Technology Advisory Board.

  October 16, 2017

   · 

  4 min read
• Concordia Continues Discussions With Stakeholders; Defers Unsecured Interest Payment Due October 16th As It Works Toward Realignment Of Its Capital Structure

  Concordia today announced that in conjunction with its ongoing efforts to realign its capital structure, it has decided to use a 30-day grace period to defer the payment of approximately $26M of interest due today on its $735M unsecured notes.

  October 16, 2017

   · 

  7 min read